Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2019-03-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
独立董事关于追加公司2018年日常关联交易额度的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval for an increase in the company's 2018 daily related-party transaction limit. It references regulatory guidelines and confirms compliance with laws and fairness principles. The document is short (433 characters) and is a formal opinion or certification rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data. This fits best under Regulatory Filings (RNS) as it is a compliance-related certification and does not match other specific categories like Audit Report or Management Reports.
2019-03-25 Chinese
独立董事关于公司2019年与控股股东日常关联交易预估的事前认可意见
Governance Information Classification · 95% confidence The document is an independent directors' pre-approval opinion on the company's 2019 estimated daily related-party transactions with controlling shareholders. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange listing rules. The content focuses on governance and compliance with related-party transaction rules, rather than financial results or report publication. The document length is short (473 characters), and it is a formal opinion statement by independent directors regarding governance matters. This fits best under Governance Information (CGR), which covers reports detailing internal rules, board structure, and governance practices, including independent directors' opinions on related-party transactions.
2019-03-25 Chinese
独立董事对《2018年年度报告》审核的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' review opinion on the 2018 annual report of Kunming Pharmaceutical Corporation. It references the 2018 annual report and states compliance with laws and regulations, but it is a standalone audit opinion or independent directors' statement rather than the full annual report itself. The document length is very short (391 characters), and it does not contain the full financial statements or detailed company activity. Therefore, it fits the category of an Audit Report / Information (AR) rather than the full Annual Report (10-K). FY 2018
2019-03-25 Chinese
独立董事关于公司2019年与重要股东日常关联交易预估的事前认可意见
Governance Information Classification · 95% confidence The document is an independent director's pre-approval opinion on the company's estimated daily related-party transactions with major shareholders for the year 2019. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange listing rules. The content focuses on governance and compliance with laws and company articles regarding related-party transactions. It does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. The document is a governance-related statement by independent directors about related-party transactions, which fits best under Governance Information (CGR).
2019-03-25 Chinese
2018年度社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled '2018 年度社会责任报告' which translates to '2018 Annual Social Responsibility Report'. It contains detailed information about the company's environmental protection efforts, pollution emissions data, safety production, governance, and social responsibility practices. The content focuses extensively on environmental data such as emissions, waste management, noise levels, and compliance with environmental regulations. There is no indication that this is an annual financial report, audit report, or any other financial filing. Instead, it aligns with the description of Environmental & Social Information (ESG) reports, which detail the company's performance on environmental, social, and governance factors. The document length is substantial and contains substantive data, not just an announcement or summary. Therefore, the appropriate classification is Environmental & Social Information (SR).
2019-03-22 Chinese
2018年度审计与风险控制委员会履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2018年度审计与风险控制委员会履职报告" which translates to the "2018 Annual Audit and Risk Control Committee Performance Report". It details the activities, meetings, and evaluations of the Audit and Risk Control Committee for the year 2018. The content includes descriptions of audit communications, committee meetings, opinions on audit work, and internal control guidance. It does not contain full financial statements or comprehensive financial data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a standalone report focused on audit committee activities and oversight, which aligns with the definition of an Audit Report / Information (AR). The document length is 2145 characters, which is relatively short but contains substantive content about audit committee work rather than just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2018
2019-03-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.